Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study

Abstract

Background/Purpose

Long-term anticoagulation is the standard treatment for thrombotic antiphospholipid syndrome (APS). However, in daily practice, the question of withdrawing anticoagulation may arise, without any evidence-based recommendations. This study aimed to assess outcomes in APS patients after anticoagulation withdrawal.

Methods

Thrombotic APS patients followed in our centre, whose anticoagulation was withdrawn after APS diagnosis, were retrospectively selected, and were match-controlled with patients under anticoagulation, based on sex, age, APS clinical phenotype and disease duration.

Results

Thirty cases with anticoagulation withdrawal were included. Median follow-up was 51 months (12–124). The risk of thrombotic relapse was higher in cases compared to controls (7.3% versus 1.5% patient-year (p = 0.01); hazard ratio 4.8; 95% confidence interval (1.4–16.7)). Male gender, anti-β2GP1 and triple positivity at inclusion were predictive factors for thrombotic relapse. Conversely, aspirin prescription was a protective factor against relapses. Persistence of LA, anti-β2GP1 and triple positivity over time were associated with a higher risk of thrombosis and aPL disappearance with a lower risk.

Conclusion

In our study, anticoagulation withdrawal was associated with an increased risk of thrombotic relapse. Our findings emphasize the influence of anti-β2GP1 and triple positivity persistence over time on the risk of relapse and the benefit of aspirin prescription when anticoagulation has been withdrawn.

Keywords

Anticoagulant therapy antiphospholipid syndrome antiphospholipid antibody relapse thrombosis

Get full access to this article

View all access options for this article.

References

Cervera

Piette

Font

et al.

Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019–1027.

Miyakis

Lockshin

Atsumi

et al.

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Kearon

Gent

Hirsh

et al.

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901–907.

Rosove

Brewer

. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303–308.

Ruiz-Irastorza

Cuadrado

Ruiz-Arruza

et al.

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206–218.

Zuily

Rat

Regnault et al.

Impairment of quality of life in patients with antiphospholipid syndrome. Lupus 2015; 24: 1161–1168.

Pengo

Ruffatti

Legnani

et al.

Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237–242.

Bertero

Bazzan

Carignola

et al.

Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): Demographic features, risk factors, clinical and laboratory profile. Lupus 2012; 21: 806–809.

Cervera

Khamashta

Shoenfeld

et al.

Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68: 1428–1432.

10.

Pengo

Tripodi

Reber

et al.

Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737–1740.

11.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

12.

Turiel

Sarzi-Puttini

Peretti

et al.

Thrombotic risk factors in primary antiphospholipid syndrome: A 5-year prospective study. Stroke J Cereb Circ 2005; 36: 1490–1494.

13.

Bazzan

Vaccarino

Stella

et al.

Thrombotic recurrences and bleeding events in APS vascular patients: A review from the literature and a comparison with the APS Piedmont Cohort. Autoimmun Rev 2013; 12: 826–831.

14.

Schulman

Svenungsson

Granqvist

. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104: 332–338.

15.

Heit

Mohr

Silverstein

Petterson

O’Fallon

Melton

3rd . Predictors of recurrence after deep vein thrombosis and pulmonary embolism: A population-based cohort study. Arch Intern Med 2000; 160: 761–768.

16.

Prandoni

Noventa

Ghirarduzzi

et al.

The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199–205.

17.

Garcia

Akl

Carr

Kearon

. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: A systematic review. Blood 2013; 122: 817–824.

18.

Forastiero

Martinuzzo

Pombo

et al.

A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231–1238.

19.

Erkan

Barbhaiya

George

Sammaritano

Lockshin

. Moderate versus high-titer persistently anticardiolipin antibody positive patients: Are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information? Lupus 2010; 19: 613–619.

20.

Pengo

Biasiolo

Pegoraro

Cucchini

Noventa

Iliceto

. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147–1152.

21.

Hernández-Molina

Espericueta-Arriola

Cabral

. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol 2013; 31: 382–388.

22.

Nash

Camilleri

Kunka

Mackie

Machin

Cohen

. The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies. J Thromb Haemost 2004; 2: 1077–1081.

23.

Pengo

Ruffatti

Del Ross

et al.

Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost 2013; 11: 1527–1531.

24.

Criado-García

Fernández-Puebla

Jiménez

Velasco

Santamaría

Blanco-Molina

. Anticoagulation treatment withdrawal in primary antiphospholipid syndrome when anticardiolipin antibodies become negative [article in Spanish]. Rev Clín Esp 2008; 208: 135–137.

25.

Coloma Bazán

Donate López

Moreno Lozano

Cervera

Espinosa

. Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. Immunol Res 2013; 56: 358–361.

26.

Okuma

Kitagawa

Yasuda

Tokuoka

Takagi

. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci 2009; 7: 15–18.

27.

Tan

Thong

Shivananda

Han

Chng

. Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort. Lupus 2009; 18: 752–758.